These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 30511198

  • 21. [Pharmacological treatment of NASH].
    Serfaty L.
    Presse Med; 2019 Dec; 48(12):1489-1495. PubMed ID: 31757735
    [Abstract] [Full Text] [Related]

  • 22. New Drugs for NASH and HIV Infection: Great Expectations for a Great Need.
    Guaraldi G, Maurice JB, Marzolini C, Monteith K, Milic J, Tsochatzis E, Bhagani S, Morse CG, Price JC, Ingiliz P, Lemoine M, Sebastiani G, SHIVER Network.
    Hepatology; 2020 May; 71(5):1831-1844. PubMed ID: 32052857
    [Abstract] [Full Text] [Related]

  • 23. The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials.
    Zhou J, Chen Y, Yu J, Li T, Lu Z, Chen Y, Zhang X, Ye F.
    Medicine (Baltimore); 2021 Mar 26; 100(12):e24884. PubMed ID: 33761646
    [Abstract] [Full Text] [Related]

  • 24. The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
    Zhao J, Li B, Zhang K, Zhu Z.
    Medicine (Baltimore); 2024 Feb 16; 103(7):e37271. PubMed ID: 38363900
    [Abstract] [Full Text] [Related]

  • 25. Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis.
    Fujinaga Y, Kawaratani H, Kaya D, Tsuji Y, Ozutsumi T, Furukawa M, Kitagawa K, Sato S, Nishimura N, Sawada Y, Takaya H, Kaji K, Shimozato N, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H.
    Int J Mol Sci; 2020 Aug 04; 21(15):. PubMed ID: 32759852
    [Abstract] [Full Text] [Related]

  • 26. Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men.
    van den Hoek AM, Verschuren L, Caspers MPM, Worms N, Menke AL, Princen HMG.
    Sci Rep; 2021 Mar 03; 11(1):5050. PubMed ID: 33658534
    [Abstract] [Full Text] [Related]

  • 27. Lansoprazole prevents the progression of liver fibrosis in non-alcoholic steatohepatitis model rats.
    Nishi T, Yamamoto Y, Yamagishi N, Iguchi M, Tamai H, Ito T, Tsuruo Y, Ichinose M, Kitano M, Ueyama T.
    J Pharm Pharmacol; 2018 Mar 03; 70(3):383-392. PubMed ID: 29355950
    [Abstract] [Full Text] [Related]

  • 28. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
    Hayashizaki-Someya Y, Kurosaki E, Takasu T, Mitori H, Yamazaki S, Koide K, Takakura S.
    Eur J Pharmacol; 2015 May 05; 754():19-24. PubMed ID: 25701721
    [Abstract] [Full Text] [Related]

  • 29. [Treatment of non-alcoholic fatty liver disease].
    Heebøll S, Vilstrup H, Grønbæk H.
    Ugeskr Laeger; 2018 Jul 30; 180(31):. PubMed ID: 30064623
    [Abstract] [Full Text] [Related]

  • 30. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
    Jouihan H, Will S, Guionaud S, Boland ML, Oldham S, Ravn P, Celeste A, Trevaskis JL.
    Mol Metab; 2017 Nov 30; 6(11):1360-1370. PubMed ID: 29107284
    [Abstract] [Full Text] [Related]

  • 31. Characterization of six clinical drugs and dietary intervention in the non-obese CDAA-HFD mouse model of MASH and progressive fibrosis.
    Nielsen MH, Nøhr-Meldgaard J, Møllerhøj MB, Oró D, Pors S, Andersen MW, Kamzolas I, Petsalaki E, Vacca M, Harder LM, Perfield JW, Veidal S, Hansen HH, Feigh M.
    Am J Physiol Gastrointest Liver Physiol; 2024 Oct 15. PubMed ID: 39404770
    [Abstract] [Full Text] [Related]

  • 32. MicroRNA-21 is associated with fibrosis in a rat model of nonalcoholic steatohepatitis and serves as a plasma biomarker for fibrotic liver disease.
    Takeuchi-Yorimoto A, Yamaura Y, Kanki M, Ide T, Nakata A, Noto T, Matsumoto M.
    Toxicol Lett; 2016 Sep 06; 258():159-167. PubMed ID: 27320964
    [Abstract] [Full Text] [Related]

  • 33. Reversal of NASH fibrosis with pharmacotherapy.
    Alukal JJ, Thuluvath PJ.
    Hepatol Int; 2019 Sep 06; 13(5):534-545. PubMed ID: 31363910
    [Abstract] [Full Text] [Related]

  • 34. Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.
    Chong LW, Hsu YC, Lee TF, Lin Y, Chiu YT, Yang KC, Wu JC, Huang YT.
    BMC Gastroenterol; 2015 Feb 15; 15():22. PubMed ID: 25886887
    [Abstract] [Full Text] [Related]

  • 35. INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis.
    Roth JD, Feigh M, Veidal SS, Fensholdt LK, Rigbolt KT, Hansen HH, Chen LC, Petitjean M, Friley W, Vrang N, Jelsing J, Young M.
    World J Gastroenterol; 2018 Jan 14; 24(2):195-210. PubMed ID: 29375205
    [Abstract] [Full Text] [Related]

  • 36. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.
    Loomba R, Sanyal AJ, Kowdley KV, Terrault N, Chalasani NP, Abdelmalek MF, McCullough AJ, Shringarpure R, Ferguson B, Lee L, Chen J, Liberman A, Shapiro D, Neuschwander-Tetri BA.
    Gastroenterology; 2019 Jan 14; 156(1):88-95.e5. PubMed ID: 30222962
    [Abstract] [Full Text] [Related]

  • 37. Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis.
    Pizarro M, Solís N, Quintero P, Barrera F, Cabrera D, Rojas-de Santiago P, Arab JP, Padilla O, Roa JC, Moshage H, Wree A, Inzaugarat E, Feldstein AE, Fardella CE, Baudrand R, Riquelme A, Arrese M.
    Liver Int; 2015 Sep 14; 35(9):2129-38. PubMed ID: 25646700
    [Abstract] [Full Text] [Related]

  • 38. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.
    Hameed B, Terrault NA, Gill RM, Loomba R, Chalasani N, Hoofnagle JH, Van Natta ML, NASH CRN.
    Aliment Pharmacol Ther; 2018 Mar 14; 47(5):645-656. PubMed ID: 29333665
    [Abstract] [Full Text] [Related]

  • 39. Deletion of nardilysin prevents the development of steatohepatitis and liver fibrotic changes.
    Ishizu-Higashi S, Seno H, Nishi E, Matsumoto Y, Ikuta K, Tsuda M, Kimura Y, Takada Y, Kimura Y, Nakanishi Y, Kanda K, Komekado H, Chiba T.
    PLoS One; 2014 Mar 14; 9(5):e98017. PubMed ID: 24849253
    [Abstract] [Full Text] [Related]

  • 40. Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats.
    Nakano T, Cheng YF, Lai CY, Hsu LW, Chang YC, Deng JY, Huang YZ, Honda H, Chen KD, Wang CC, Chiu KW, Jawan B, Eng HL, Goto S, Chen CL.
    J Hepatol; 2011 Aug 14; 55(2):415-25. PubMed ID: 21184788
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.